Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 2 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood. 2024 Jan 25;143(4):336-341. doi: 10.1182/blood.2023021579.
Blood. 2024.
PMID: 37647641
Safety evaluation of ruxolitinib for treating myelofibrosis.
Galli S, McLornan D, Harrison C.
Galli S, et al.
Expert Opin Drug Saf. 2014 Jul;13(7):967-76. doi: 10.1517/14740338.2014.916273. Epub 2014 Jun 4.
Expert Opin Drug Saf. 2014.
PMID: 24896661
Review.
Item in Clipboard
Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, McLornan DP.
Mwirigi A, et al. Among authors: galli s.
Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22.
Br J Haematol. 2014.
PMID: 25048366
Free article.
No abstract available.
Item in Clipboard
Cite
Cite